PrimeRFP SCOUT · Federal Contract Recompete Brief

SPE2DB23FPQS84561154752!ocrevus 300 MG 10 ML VIAL 10ml — Dms Pharmaceutical Group Inc

Dms Pharmaceutical Group Inc holds $737.3M across 100,503 federal awards, concentrated at Department of Defense (DOD). This PIID sits alongside 1 related award under parent SPE2DB20D9127. PoP ended Jun 26, 2023 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

Dla Troop Support

Awarding office

Dms Pharmaceutical Group Inc

Recipient

Jun 26, 2023

PoP end

$251K

Obligated

$251K

Potential

424210

NAICS

6505

PSC

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Dms Pharmaceutical Group Inc — $90

Contract facts

Federal

Contract numberSPE2DB23FPQS8

Also listed asSPE2DB20D9127-SPE2DB23FPQS8

AgencyDla Troop Support

Awarding officeDla Troop Support

Awarding agencyDepartment of Defense (DOD)

Funding agencyDepartment of Defense (DOD)

IncumbentDms Pharmaceutical Group Inc

CAGE1UNB0

UEIPX72BSBQTKJ3

NAICS424210

No full NAICS 424210 intel page yet. Browse NAICS intelligence

PSC6505

Parent IDIQ / IDVSPE2DB20D9127

Place of performancePARK RIDGE IL

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition

PoP startJun 2, 2023

PoP end (current)Jun 26, 2023

Obligated$251K

Current value$251K

Potential value$251K

4561154752!OCREVUS 300 MG/10 ML VIAL 10ML is a federal award for Dla Troop Support held by Dms Pharmaceutical Group Inc. Estimated value $251K ($251K obligated). Current period of performance ends Jun 26, 2023. Place of performance: PARK RIDGE IL.

4561154752!OCREVUS 300 MG/10 ML VIAL 10ML

Recompete timing

Public

● Past PoP end (1152 days ago)

Current PoP ended Jun 26, 2023 (1152 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Incumbent footprint

Public record

Dms Pharmaceutical Group Inc — $737.3M obligated across 100,503 awards (firm-wide, all agencies) · lead buyer Department of Defense (DOD).

% of firm-wide obligated ($737.3M) · all agencies

Department of Defense (DOD)$737.1M · 100%Department of Veterans Affairs (VA)$193K · 0%

Open full company profile →

Related awards

Same parent · incumbent

SPE2D026F0120

8511978882!OTHER MEDICAL

$248K

Apr 26, 2027

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract SPE2DB23FPQS8?

SPE2DB23FPQS8 (4561154752!ocrevus 300 MG 10 ML VIAL 10ml) is a Dla Troop Support award with a potential value of $251K, currently held by Dms Pharmaceutical Group Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded SPE2DB23FPQS8?

Dla Troop Support awarded SPE2DB23FPQS8 to Dms Pharmaceutical Group Inc (potential $251K).

Who is the incumbent on SPE2DB23FPQS8?

Dms Pharmaceutical Group Inc is the incumbent with $737.3M across 100503 related awards in SCOUT’s public footprint. The current period of performance ends Jun 26, 2023.

When does Dms Pharmaceutical Group Inc’s SPE2DB23FPQS8 come up for recompete?

SCOUT tracks a period-of-performance end of Jun 26, 2023. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Aug 1, 2026 · refreshed monthlyLatest procurement action Jun 2, 2023